Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

Blood (2022) 140 (Supplement 1): 231–233.

https://doi.org/10.1182/blood-2022-170463

Published: 2022

Journal Articles

MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study

Blood (2022) 140 (Supplement 1): 222–223.

https://doi.org/10.1182/blood-2022-166700

Published: 2022

Journal Articles

Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial

Blood (2022) 140 (Supplement 1): 1459–1463.

https://doi.org/10.1182/blood-2022-158024

Published: 2022

Journal Articles

Expansion of T Follicular Helper Cells in NLC Co-Cultures Reinforces the Concept of Co-Evolution of CLL and Supportive T Helper Cell Clones

Alicia Vaca, Nikolaos Ioannou, Mariela Sivina, Elisavet Vlachonikola, Karen Clise-Dwyer, Ekaterina Kim, Dan Li, Qing Ma, Alessandra Ferrajoli, Zeev E. Estrov, William G. Wierda, Piers E.M. Patten, Alan G. Ramsay, Jan A. Burger

Blood (2021) 138 (Supplement 1): 3716.

https://doi.org/10.1182/blood-2021-151351

Published: 2021

Journal Articles

Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England

Blood (2019) 134 (Supplement_1): 767.

https://doi.org/10.1182/blood-2019-124177

Published: 2019

Journal Articles

Allogeneic Anti-CD19 CAR T Cells Manufactured from Healthy Donors Provide a Unique Cellular Product with Distinct Phenotypic Characteristics Compared to CAR T Cells Generated from Patients with Mature B Cell Malignancies

Charlotte Graham, MRCP, BSc, MBBS, Agnieszka Jozwik, PhD, Ruby Quartey-Papafio, Nikolaos Ioannou, PhD MSc, BSc, Ana M Metelo, PhD, Carlo Scala, PhD, Glenda Dickson, PhD, Orla Stewart, Maria Almena-Carrasco, Elisa Peranzoni, Alan G. Ramsay, BSc,MSc,PhD, Sandra Dupouy, Pharm.D, PhD, Farzin Farzaneh, PhD, Piers E.M. Patten, BSc, MRCP, MRCPath, PhD, Andrea Pepper, PhD, Reuben Benjamin, FRCPath, MRCP, MBBS, PhD

Blood (2019) 134 (Supplement_1): 3228.

https://doi.org/10.1182/blood-2019-123018

Published: 2019

Journal Articles

Eliciting Anti-Tumor T Cell Immunity in Chronic Lymphocytic Leukemia (CLL) with PD-L1/PD-1 Blockade Is Enhanced By Avadomide Immunotherapy through the Triggering of Immunogenic Interferon Signaling

Nikolaos Ioannou, PhD MSc, BSc, Patrick R. Hagner, PhD, Fadi Towfic, PhD, Anita K. Gandhi, PhD, Kostas Stamatopoulos, MD PhD, Piers E.M. Patten, BSc, MRCP, MRCPath, PhD, Anna Vardi, MD PhD, Alan G. Ramsay, BSc,MSc,PhD

Blood (2018) 132 (Supplement 1): 237.

https://doi.org/10.1182/blood-2018-99-111605

Published: 2018

Journal Articles

Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study

Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Andy Rawstron, BSc, PhD, Kristian Brock, MSc, BSc, Samuel Munoz Vicente, MSc, Francesca Yates, PhD, Rebecca Bishop, BSc, Donald Macdonald, Christopher Fegan, MD, Alison McCaig, PhD, Anna Schuh, MD PhD, Andrew Pettitt, FRCPath, PhD, John G. Gribben, Piers E.M. Patten, BSc, MRCP, MRCPath, PhD, Stephen Devereux, PhD, Adrian Bloor, MA MB BChir PhDFCRP FRCPath, Christopher P. Fox, MD PhD, Francesco Forconi, MD DM, PhD FRCPath, Talha Munir

Blood (2018) 132 (Supplement 1): 182.

https://doi.org/10.1182/blood-2018-182

Published: 2018

Journal Articles

IGHV-D-J Ultra-Deep Sequencing Reveals APOBEC and AID Targeted Mutations during Clonal Evolution of CLL in a Xenograft Mouse Model

Charles C. Chu, PhD, Piers E.M. Patten, BSc, MRCP, MRCPath, PhD, Thomas MacCarthy, PhD, Chaohui Yuan, MS, Xiao-Jie Yan, MD PhD, Jacqueline C. Barrientos, MD, Jonathan E. Kolitz, MD, Steven L. Allen, MD, Kanti R. Rai, MD, Nicholas Chiorazzi, MD

Blood (2014) 124 (21): 300.

https://doi.org/10.1182/blood.V124.21.300.300

Published: 2014

Journal Articles

Autologous Stem Cell Transplantation Achieves Long-Term Survival in a Selected CNS Lymphoma Population

Anjum Bashir Khan, MBChB, MRCP, Alesia Abigael Hunt, MBChB, Victoria T Potter, MD FRCPA, FRACP, Shireen Kassam, MBBS, Deborah Yallop, MB, BS, BSc.(hons), MRCP, FRCPath, Piers E.M. Patten, BSc, MRCP, MRCPath, PhD, Stephen Devereux, MD PhD FRCPath, Ghulam Mufti, MD DM, FRCP, FRCPath, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Robert E. Marcus, MBBS, FRCP, FRCPath

Blood (2014) 124 (21): 1197.

https://doi.org/10.1182/blood.V124.21.1197.1197

Published: 2014

Journal Articles

Lenalidomide Promotes The Expansion Of CD8 T Cells With An Effector Memory Phenotype In a Murine Xenograft Model Of Chronic Lymphocytic Leukemia

Rita Simone, PhD, Sonia Marsilio, PhD, Piers E.M. Patten, MD, PhD, Gerardo Ferrer, PhD, Shih-Shih Chen, Ph.D., Xiao J. Yan, MD, PhD, Stefano Vergani, Msc, Andrea Nicola Mazzarello, PhD, Jacqueline C. Barrientos, MD, Steven L. Allen, M.D., Jonathan E. Kolitz, MD, Kanti R. Rai, MD, Nicholas Chiorazzi, MD

Blood (2013) 122 (21): 119.

https://doi.org/10.1182/blood.V122.21.119.119

Published: 2013

Journal Articles

Intraclonal Complexity Of CLL Fractions In Cell Proliferation Rates, Gene Expression Signatures, and Responses To Autologous T-Cell Help In Peripheral blood and Secondary Lymphoid Tissues

Shih-Shih Chen, Thomas M. Herndon, MD, Claire Emson, PhD, John C. Riches, MD, Fabienne McClanahan, MD, Timothy Tong, Xiao-Jie Yan, MD PhD, Piers E.M. Patten, MD, PhD, John Gribben, MD, DSc, Adrian Wiestner, MD, PhD, Nicholas Chiorazzi, MD

Blood (2013) 122 (21): 115.

https://doi.org/10.1182/blood.V122.21.115.115

Published: 2013

Journal Articles

Evaluation of IGHV Ultra-Deep Sequences for Activation-Induced Deaminase Characteristics in CLL Cells after T Cell Stimulation

Charles C. Chu, PhD, Piers E.M. Patten, MD, PhD, Thomas MacCarthy, PhD, Xiao-Jie Yan, MD PhD, Jacqueline C. Barrientos, MD, Jonathan E. Kolitz, MD, Steven L. Allen, MD, Kanti R. Rai, MD, Nicholas Chiorazzi, MD

Blood (2013) 122 (21): 2583.

https://doi.org/10.1182/blood.V122.21.2583.2583

Published: 2013

Journal Articles

Ultra-Deep Sequencing of De Novo IGHV Mutations in Activated CLL Cells: Evidence for Activation-Induced Deaminase Function.

Piers E.M. Patten, MBBCh, PhD, Thomas MacCarthy, PhD, Xiao-Jie Yan, MD PhD, Jonathan E. Kolitz, MD, Steven L. Allen, MD, Jacqueline C. Barrientos, MD, Kanti R. Rai, MD, Nicholas Chiorazzi, MD, Charles C. Chu, PhD

Blood (2012) 120 (21): 2545.

https://doi.org/10.1182/blood.V120.21.2545.2545

Published: 2012

Journal Articles

CLL Cells Can Diversify, Switch, and Differentiate in Response to Autologous T Cell Stimuli Present in a Murine Adoptive Transfer Model

Piers E.M. Patten, MBBCh, PhD, Shih-Shih Chen, Ph.D., Davide Bagnara, Ph.D., Rita Simone, PhD, Sonia Marsilio, PhD, Xiao-Jie Yan, MD PhD, Jacqueline C. Barrientos, MD, Jonathan E. Kolitz, MD, Steven L. Allen, MD, Kanti R. Rai, MD, Thomas MacCarthy, PhD, Charles C. Chu, PhD, Nicholas Chiorazzi, MD

Blood (2012) 120 (21): 315.

https://doi.org/10.1182/blood.V120.21.315.315

Published: 2012

Journal Articles

Human CLL Intraclonal Fractions Differ in Their Abilities to Respond to, Elicit, and Suppress Pro-Engraftment and Growth Signals From Autologous T Cells in a Murine Adoptive Transfer Model

Shih-Shih Chen, Ph.D., Piers E.M. Patten, MBBCh, PhD, Rita Simone, PhD, Sonia Marsilio, PhD, Jacqueline C. Barrientos, MD, Jonathan E. Kolitz, MD, Steven L. Allen, MD, Kanti R. Rai, M.D., Nicholas Chiorazzi, MD

Blood (2012) 120 (21): 316.

https://doi.org/10.1182/blood.V120.21.316.316

Published: 2012

Journal Articles

In-Situ Proliferation May Explain the Persistence of Host Derived Langerhans Cells Following Allogeneic Hematopoietic Stem Cell Transplantation with Reduced Intensity Conditioning.

Julie Richards, PhD, Laurence Pearce, BSc, Piers E.M. Patten, MD, Andrea G.S. Buggins, PhD, Aloyisius Y. Ho, MD, Anthony Pagliuca, MD, Ghulam J. Mufti, MD, Stephen Devereux, MD, PhD

Blood (2007) 110 (11): 1196.

https://doi.org/10.1182/blood.V110.11.1196.1196

Published: 2007

Journal Articles

CD38 Expression in B-CLL Is Dynamic and Changes Due to Contact with Activating Stimuli Found within the Leukaemic Microenvironment.

Piers E.M. Patten, MD, Andrea G.S. Buggins, PhD, Julie Richards, PhD, Andrew Wotherspoon, MD, Terry John Hamblin, MD, Ghulam Mufti, MD, Stephen Devereux, MD PhD

Blood (2006) 108 (11): 2798.

https://doi.org/10.1182/blood.V108.11.2798.2798

Published: 2006

Journal Articles

IL-6 Production by B-CLL Cells Plays a Critical Role in the Inhibition of T Cell Activation and Proliferation and Promotes a Th2 Response in Normal T Lymphocytes.

Andrea G.S. Buggins, PhD, Piers E.M. Patten, MD, Julie Richards, PhD, Stephen J. Orr, MSC, Ghulam J. Mufti, MD, Nicholas S.B. Thomas, PhD, Stephen Devereux, MD PhD

Blood (2006) 108 (11): 2808.

https://doi.org/10.1182/blood.V108.11.2808.2808

Published: 2006

Journal Articles

The Acquired CD40L Deficiency in B-CLL Is Reversible and Due To Contact Dependant and Independent Factors.

Andrea G.S. Buggins, Ph.D., Julie Richards, Ph.D., Piers E.M. Patten, M.B.Ch.B., Ghulam J. Mufti, FRCP, FRCPath, DM., Stephen Devereux, FRCP, FRCPath, Ph.D.

Blood (2004) 104 (11): 2813.

https://doi.org/10.1182/blood.V104.11.2813.2813

Published: 2004

NARROW

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study

Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial

Expansion of T Follicular Helper Cells in NLC Co-Cultures Reinforces the Concept of Co-Evolution of CLL and Supportive T Helper Cell Clones

Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England

Allogeneic Anti-CD19 CAR T Cells Manufactured from Healthy Donors Provide a Unique Cellular Product with Distinct Phenotypic Characteristics Compared to CAR T Cells Generated from Patients with Mature B Cell Malignancies

Eliciting Anti-Tumor T Cell Immunity in Chronic Lymphocytic Leukemia (CLL) with PD-L1/PD-1 Blockade Is Enhanced By Avadomide Immunotherapy through the Triggering of Immunogenic Interferon Signaling

Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study

IGHV-D-J Ultra-Deep Sequencing Reveals APOBEC and AID Targeted Mutations during Clonal Evolution of CLL in a Xenograft Mouse Model

Autologous Stem Cell Transplantation Achieves Long-Term Survival in a Selected CNS Lymphoma Population

Lenalidomide Promotes The Expansion Of CD8 T Cells With An Effector Memory Phenotype In a Murine Xenograft Model Of Chronic Lymphocytic Leukemia

Intraclonal Complexity Of CLL Fractions In Cell Proliferation Rates, Gene Expression Signatures, and Responses To Autologous T-Cell Help In Peripheral blood and Secondary Lymphoid Tissues

Evaluation of IGHV Ultra-Deep Sequences for Activation-Induced Deaminase Characteristics in CLL Cells after T Cell Stimulation

Ultra-Deep Sequencing of De Novo IGHV Mutations in Activated CLL Cells: Evidence for Activation-Induced Deaminase Function.

CLL Cells Can Diversify, Switch, and Differentiate in Response to Autologous T Cell Stimuli Present in a Murine Adoptive Transfer Model

Human CLL Intraclonal Fractions Differ in Their Abilities to Respond to, Elicit, and Suppress Pro-Engraftment and Growth Signals From Autologous T Cells in a Murine Adoptive Transfer Model

In-Situ Proliferation May Explain the Persistence of Host Derived Langerhans Cells Following Allogeneic Hematopoietic Stem Cell Transplantation with Reduced Intensity Conditioning.

CD38 Expression in B-CLL Is Dynamic and Changes Due to Contact with Activating Stimuli Found within the Leukaemic Microenvironment.

IL-6 Production by B-CLL Cells Plays a Critical Role in the Inhibition of T Cell Activation and Proliferation and Promotes a Th2 Response in Normal T Lymphocytes.

The Acquired CD40L Deficiency in B-CLL Is Reversible and Due To Contact Dependant and Independent Factors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only